title: CNK1 is a novel Akt interaction partner that promotes cell proliferation through the Akt-FoxO signalling axis.
abstract: The scaffold proteins connector enhancer of KSR (CNK) participate in Raf-, Rho- and NF-kappaB-dependent signalling and promote cell differentiation and invasion. In this study, we demonstrate that CNK1 downregulation inhibits, whereas CNK1 overexpression stimulates the proliferation of breast cancer cells and human embryonic kidney cells, respectively. This stimulatory effect depends on a functional phosphatidylinositol-3 kinase (PI3K) pathway because treatment of cells with the PI3K inhibitor, LY294002, abrogates CNK1-induced proliferation. CNK1 interacts with the PI3K effector Akt and knockdown of CNK1 decreases Akt activity in breast cancer cells. CNK1 controls Akt-dependent phosphorylation and transcriptional activity of FoxO, which is a negative regulator of proliferation. Consistent with this, CNK1-induced cell proliferation is blocked by FoxO overexpression. Moreover, CNK1 regulates anchorage-independent proliferation and focus formation of breast cancer cells. CNK1 is predominantly localized at the plasma membrane of breast cancer cells, whereas in non-transformed mammary epithelial cells, CNK1 is cytoplasmatic. Accordingly, CNK1 is found preferentially at the plasma membrane in carcinoma in situ and invasive breast cancer tumours compared with normal breast tissue sections. Analysis of multiple breast cancer samples reveals that CNK1-negative tumours show less Akt activity. Thus, CNK1 promotes oncogenic signalling through Akt in breast cancer cell lines and tumours.
authors.affiliation: Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
authors.forename: R D
authors.initials: RD
authors.lastname: Fritz
authors.forename: Z
authors.initials: Z
authors.lastname: Varga
authors.forename: G
authors.initials: G
authors.lastname: Radziwill
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D051858:Forkhead Transcription Factors / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism*; D009857:Oncogenes / Q000235:genetics; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D015398:Signal Transduction
chemical_list: C500833:CNKSR1 protein, human; D051858:Forkhead Transcription Factors; D047908:Intracellular Signaling Peptides and Proteins; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt
references.citation: Mol Cancer Res. 2010 Mar;8(3):395-406
references.pmid: 20197385
references.citation: Cell. 2006 Oct 6;127(1):125-37
references.pmid: 16962653
references.citation: Oncogene. 2007 May 14;26(22):3143-58
references.pmid: 17496912
references.citation: EMBO J. 2005 Feb 9;24(3):487-98
references.pmid: 15660123
references.citation: Curr Biol. 2005 Mar 8;15(5):405-12
references.pmid: 15753034
references.citation: Cell. 2007 Jun 29;129(7):1261-74
references.pmid: 17604717
references.citation: EMBO J. 1996 Dec 2;15(23):6541-51
references.pmid: 8978681
references.citation: J Biol Chem. 2004 Jul 9;279(28):29247-54
references.pmid: 15075335
references.citation: Science. 2005 Feb 18;307(5712):1098-101
references.pmid: 15718470
references.citation: Mol Cell. 2002 Jul;10(1):151-62
references.pmid: 12150915
references.citation: Mol Cell Biol. 2004 Feb;24(4):1736-46
references.pmid: 14749388
references.citation: BMC Cancer. 2007 Jan 17;7:12
references.pmid: 17233884
references.citation: FASEB J. 2003 Nov;17(14):2048-60
references.pmid: 14597674
references.citation: Oncogene. 2008 Apr 7;27(16):2276-88
references.pmid: 18391970
references.citation: Nat Rev Cancer. 2002 Jul;2(7):489-501
references.pmid: 12094235
references.citation: Biochem Biophys Res Commun. 2005 Dec 30;338(4):1906-12
references.pmid: 16289034
references.citation: J Biol Chem. 2005 Jun 24;280(25):24205-11
references.pmid: 15845549
references.citation: Oncogene. 1998 Jul 23;17(3):313-25
references.pmid: 9690513
references.citation: EMBO J. 2008 May 7;27(9):1399-410
references.pmid: 18388859
references.citation: Curr Biol. 2004 Mar 9;14(5):439-45
references.pmid: 15028221
references.citation: J Cell Sci. 2007 Aug 1;120(Pt 15):2479-87
references.pmid: 17646672
references.citation: Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13571-6
references.pmid: 12271141
references.citation: Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11757-62
references.pmid: 16085714
references.citation: J Biol Chem. 1997 Dec 12;272(50):31515-24
references.pmid: 9395488
references.citation: J Clin Invest. 2001 Feb;107(3):241-6
references.pmid: 11160144
references.citation: Nat Rev Cancer. 2002 Apr;2(4):301-10
references.pmid: 12001991
references.citation: Oncogene. 2007 May 14;26(22):3279-90
references.pmid: 17496922
references.citation: EMBO J. 2003 Oct 1;22(19):5068-78
references.pmid: 14517245
references.citation: Mol Cell. 2007 Mar 23;25(6):903-15
references.pmid: 17386266
references.citation: Biochem J. 2005 Jan 15;385(Pt 2):399-408
references.pmid: 15456405
references.citation: Cancer Immunol Immunother. 2007 Nov;56(11):1723-31
references.pmid: 17410359
references.citation: FEBS Lett. 2005 Jan 31;579(3):648-54
references.pmid: 15670823
references.citation: Cell. 1998 Oct 30;95(3):343-53
references.pmid: 9814705